Get started

Financials · ZYME

Zymeworks Inc. (ZYME) financials

For the twelve months ended Jun 30, 2026, Zymeworks Inc. reported $37.13M of revenue and -$149.99M of net income.

Revenue, TTM
$37.13M
Revenue growth, YoY
-69.8%
Net income, TTM
-$149.99M
Net margin
-404.0%
Free cash flow, TTM
-$120.54M
EPS, diluted, TTM
-$2.02
Cash
$179.41M
P/S
56.23
Market cap
$2.09B
Annual revenue$105.97M
FY2020FY2025
Annual net income-$81.13M
FY2020FY2025
Annual free cash flow-$34.53M
FY2020FY2025

ZYME revenue and earnings growth

ZYME revenueQ2 2026$4.59M

Quarter YoY
-90.6%
QoQ
+90.6%
FY YoY
+38.9%
5Y CAGR
+22.2%

ZYME revenue was $4.59M in fiscal Q2 2026 (ended Jun 30, 2026), down 90.6% from a year earlier and up 90.6% from the prior quarter. For the full fiscal 2025 it was $105.97M, up 38.9% from fiscal 2024. Compound annual growth was +22.2% over 5 years. It rose in 3 of the last 5 fiscal years.

ZYME net incomeQ2 2026-$45.02M

ZYME net income was -$45.02M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $2.32M a year earlier. For the full fiscal 2025 it was -$81.13M, compared with -$122.69M in fiscal 2024.

ZYME EPSQ2 2026-$0.62

ZYME diluted EPS was -$0.62 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0.03 a year earlier. For the full fiscal 2025 it was -$1.08, compared with -$1.62 in fiscal 2024.

ZYME free cash flowQ2 2026-$31.95M

ZYME free cash flow was -$31.95M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $11.56M a year earlier. For the full fiscal 2025 it was -$34.53M, compared with -$112.05M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue$105.97M$76.30M$76.01M$412.48M$26.68M$38.95M
Research and development$137.00M$134.62M$143.62M$208.60M$199.75M$171.20M
Selling, general and admin$61.51M$61.51M$70.45M$73.36M$42.56M$55.22M
Operating income-$92.55M-$137.11M-$138.05M$130.53M-$215.63M-$187.47M
Pre-tax income-$79.75M-$116.61M-$119.24M$135.23M-$212.36M-$180.12M
Income tax$1.38M$6.08M-$568.0K$10.89M-$516.0K$429.0K
Net income-$81.13M-$122.69M-$118.67M$124.34M-$211.84M-$180.55M
EPS, basic-$1.08-$1.62-$1.72$1.91-$4.11-$3.58
EPS, diluted-$1.08-$1.62-$1.72$1.90-$4.61-$3.58
Diluted shares75.4M75.9M68.9M65.2M52.1M50.4M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Cash and equivalents$41.16M$66.10M$157.56M$400.91M$201.87M$242.04M
Short-term investments--$216.77M$91.32M$50.74M-
Receivables$4.64M$55.81M$19.48M$33.40M$15.61M-
Current assets$248.77M$300.45M$412.93M$544.71M$288.22M-
Goodwill$12.02M$12.02M$12.02M$12.02M$12.02M-
Total assets$346.53M$463.09M$580.88M$648.73M$389.13M-
Current liabilities$42.32M$88.29M$55.76M$95.63M$71.85M-
Total liabilities$78.03M$124.32M$116.07M$155.77M$140.04M-
Shareholders' equity$268.50M$338.77M$464.81M$492.96M$249.09M$409.92M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Operating cash flow-$33.01M-$110.06M-$118.32M$144.11M-$192.45M-$151.40M
Capital expenditures$1.52M$1.99M$2.47M$8.15M$12.40M$4.31M
Free cash flow-$34.53M-$112.05M-$120.80M$135.96M-$204.85M-$155.71M
Investing cash flow$26.66M$38.76M-$207.25M-$53.85M$144.60M-$43.44M
Financing cash flow-$18.56M-$20.44M$81.87M$108.58M$8.01M$308.98M
Share repurchases$41.70M$30.05M$0$0--
Stock-based compensation$28.03M$17.79M$8.10M$4.01M$10.76M$29.12M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue growth, YoY38.9%0.4%-81.6%1446.0%-31.5%-
Operating margin-87.3%-179.7%-181.6%31.6%-808.2%-481.3%
Net margin-76.6%-160.8%-156.1%30.1%-794.0%-463.5%
Free cash flow margin-32.6%-146.8%-158.9%33.0%-767.8%-399.8%
Return on equity-30.2%-36.2%-25.5%25.2%-85.0%-44.0%
Return on assets-23.4%-26.5%-20.4%19.2%-54.4%-
Current ratio5.883.407.415.704.01-

Source: XBRL data Zymeworks Inc. files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ZYME peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ZYME$37.13M-69.8%-$149.99M-404.0%$2.09B
LLY$86.46B+45.5%$27.58B31.9%$1.27T
JNJ$99.33B+7.8%$16.09B16.2%$664.95B
ABBV$66.01B+10.7%$10.34B15.7%$514.92B
MRK$67.38B+4.9%$2.45B3.6%$361.71B
NVS$54.53B+8.4%$13.98B25.6%$310.17B
AZN$58.74B+8.6%$10.22B17.4%$289.10B
ABT$48.23B+10.0%$4.70B9.7%$190.39B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$178.51B

ZYME FAQ

8 questions
  • What is ZYME revenue?
    Zymeworks Inc. (ZYME) reported $37.13M of revenue for the twelve months ended Jun 30, 2026. That is down 69.8% from the year before. Revenue for fiscal 2025 was $105.97M.
  • Is ZYME profitable?
    No. Zymeworks Inc. reported a net loss of $149.99M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does ZYME have?
    Zymeworks Inc. reported $179.41M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is ZYME revenue growing?
    Zymeworks Inc.'s revenue changed +38.9% in fiscal 2025, to $105.97M. Its compound annual growth rate was +22.2% over 5 years.
  • What is ZYME free cash flow?
    Zymeworks Inc. generated -$120.54M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$119.34M less capital expenditures.
  • What is ZYME earnings per share?
    Diluted earnings per share were -$2.02 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did ZYME last report financial results?
    The latest statements here come from Zymeworks Inc.'s 10-Q filed on Aug 6, 2026, covering the period ended Jun 30, 2026.
  • Where does this ZYME financial data come from?
    Quantisnow builds these statements from the structured XBRL data Zymeworks Inc. files with the SEC. It is provided for information only and is not investment advice.